S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:KRMD

Repro Med Systems Stock Forecast, Price & News

$3.71
+0.21 (+6.00 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.27
Now: $3.71
$3.73
50-Day Range
$3.50
MA: $4.42
$5.48
52-Week Range
$3.27
Now: $3.71
$12.84
Volume557,467 shs
Average Volume543,532 shs
Market Capitalization$163.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
Repro Med Systems logo

Headlines

KORU Medical Systems: A Razor And Razor Blade Story
January 13, 2021 |  seekingalpha.com
Is KRMD A Good Stock To Buy Now?
December 15, 2020 |  finance.yahoo.com
Repro Med Systems launches $10M buyback program
November 17, 2020 |  seekingalpha.com
KORU Medical Systems Announces Stock Repurchase Program
November 16, 2020 |  finance.yahoo.com
Stock Alert: Repro Med Systems Tanks 30%
November 4, 2020 |  nasdaq.com
Repro-Med Systems, Inc. to Host Earnings Call
November 4, 2020 |  finance.yahoo.com
Repro Med Systems EPS misses by $0.01, misses on revenue
November 3, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRMD
CUSIPN/A
CIKN/A
Phone845-469-2042
Employees71
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.16 million
Cash Flow$0.02 per share
Book Value$0.28 per share

Profitability

Net Income$560,000.00

Miscellaneous

Market Cap$163.03 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

34th out of 1,972 stocks

Surgical & Medical Instruments Industry

5th out of 169 stocks

Analyst Opinion: 3.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
$3.71
+0.21 (+6.00 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for KRMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Repro Med Systems (NASDAQ:KRMD) Frequently Asked Questions

Is Repro Med Systems a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repro Med Systems in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Repro Med Systems stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRMD, but not buy additional shares or sell existing shares.
View analyst ratings for Repro Med Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Repro Med Systems?

Wall Street analysts have given Repro Med Systems a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Repro Med Systems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Repro Med Systems?

Repro Med Systems saw a increase in short interest in February. As of February 12th, there was short interest totaling 1,520,000 shares, an increase of 64.0% from the January 28th total of 926,700 shares. Based on an average daily trading volume, of 523,300 shares, the short-interest ratio is presently 2.9 days. Approximately 3.7% of the shares of the company are sold short.
View Repro Med Systems' Short Interest
.

When is Repro Med Systems' next earnings date?

Repro Med Systems is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Repro Med Systems
.

How were Repro Med Systems' earnings last quarter?

Repro Med Systems, Inc. (NASDAQ:KRMD) posted its earnings results on Tuesday, November, 3rd. The company reported $0.01 EPS for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.01. The company had revenue of $6.08 million for the quarter, compared to analysts' expectations of $7.21 million. Repro Med Systems had a positive trailing twelve-month return on equity of 6.79% and a negative net margin of 1.74%.
View Repro Med Systems' earnings history
.

How has Repro Med Systems' stock been impacted by Coronavirus (COVID-19)?

Repro Med Systems' stock was trading at $8.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KRMD stock has decreased by 55.0% and is now trading at $3.71.
View which stocks have been most impacted by COVID-19
.

What guidance has Repro Med Systems issued on next quarter's earnings?

Repro Med Systems updated its FY 2020 After-Hours earnings guidance on Monday, January, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24-24 million, compared to the consensus revenue estimate of $25.9 million.

What price target have analysts set for KRMD?

3 Wall Street analysts have issued 12-month target prices for Repro Med Systems' shares. Their forecasts range from $4.50 to $16.00. On average, they expect Repro Med Systems' share price to reach $8.50 in the next twelve months. This suggests a possible upside of 129.1% from the stock's current price.
View analysts' price targets for Repro Med Systems
or view top-rated stocks among Wall Street analysts.

Who are Repro Med Systems' key executives?

Repro Med Systems' management team includes the following people:
  • Mr. James M. Beck, Interim CEO & Director (Age 73, Pay $29.31k)
  • Ms. Karen Fisher, CFO, Treasurer & Corp. Sec. (Age 55, Pay $344.73k)
  • Mr. Manuel A. Marques, Chief Operating Officer (Age 48, Pay $313.52k)

Who are some of Repro Med Systems' key competitors?

What other stocks do shareholders of Repro Med Systems own?

What is Repro Med Systems' stock symbol?

Repro Med Systems trades on the NASDAQ under the ticker symbol "KRMD."

Who are Repro Med Systems' major shareholders?

Repro Med Systems' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Horton Capital Management LLC (27.00%), BlackRock Inc. (3.62%), Fuller & Thaler Asset Management Inc. (0.90%), Northern Trust Corp (0.69%), Kornitzer Capital Management Inc. KS (0.41%) and Acuitas Investments LLC (0.33%). Company insiders that own Repro Med Systems stock include Daniel S Goldberger, Donald B Pettigrew, Joseph M Jr Manko, Karen Fisher and R John Fletcher.
View institutional ownership trends for Repro Med Systems
.

Which institutional investors are selling Repro Med Systems stock?

KRMD stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, Strs Ohio, Charles Schwab Investment Management Inc., Cambridge Investment Research Advisors Inc., Bank of New York Mellon Corp, HighMark Wealth Management LLC, and Northern Trust Corp.
View insider buying and selling activity for Repro Med Systems
or view top insider-selling stocks.

Which institutional investors are buying Repro Med Systems stock?

KRMD stock was acquired by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Squarepoint Ops LLC, GSA Capital Partners LLP, JPMorgan Chase & Co., Alpha Paradigm Partners LLC, Kornitzer Capital Management Inc. KS, Royce & Associates LP, and Nuveen Asset Management LLC. Company insiders that have bought Repro Med Systems stock in the last two years include Daniel S Goldberger, Donald B Pettigrew, Joseph M Jr Manko, Karen Fisher, and R John Fletcher.
View insider buying and selling activity for Repro Med Systems
or or view top insider-buying stocks.

How do I buy shares of Repro Med Systems?

Shares of KRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Repro Med Systems' stock price today?

One share of KRMD stock can currently be purchased for approximately $3.71.

How much money does Repro Med Systems make?

Repro Med Systems has a market capitalization of $163.03 million and generates $23.16 million in revenue each year. The company earns $560,000.00 in net income (profit) each year or $0.01 on an earnings per share basis.

How many employees does Repro Med Systems have?

Repro Med Systems employs 71 workers across the globe.

What is Repro Med Systems' official website?

The official website for Repro Med Systems is www.korumedical.com.

Where are Repro Med Systems' headquarters?

Repro Med Systems is headquartered at 24 CARPENTER RD, CHESTER NY, 10918.

How can I contact Repro Med Systems?

Repro Med Systems' mailing address is 24 CARPENTER RD, CHESTER NY, 10918. The company can be reached via phone at 845-469-2042 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.